Welcome to our dedicated page for Alexandria Real Estate Eq news (Ticker: ARE), a resource for investors and traders seeking the latest updates and insights on Alexandria Real Estate Eq stock.
Alexandria Real Estate Equities, Inc. reports news as a life science real estate investment trust that owns, operates and develops collaborative Megacampus™ ecosystems in major life science innovation clusters. Company updates commonly cover operating results, funds from operations, leasing activity, rental-rate trends and property-market demand across locations such as Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City.
Recurring announcements also include quarterly common stock dividends, balance-sheet and liquidity commentary, capital recycling activity, senior note offerings, cash tender offers for outstanding debt and corporate governance or leadership matters tied to the REIT’s public-company structure.
Alexandria Real Estate Equities (NYSE: ARE) reported the tax composition of its 2025 distributions. Total distributions paid were $5.280000 per share (four quarterly payments of $1.32 each). The taxable ordinary dividend component (Box 1a) totaled $3.517008 per share, representing 66.61% of the total. Qualified dividend amounts totaled $0.762960 per share. Return of capital was $0.033264 per share and Section 199A dividends totaled $0.250008 per share. No Section 897 capital gains were reported. Stockholders are advised to consult their tax advisors for individual treatment.
Alexandria Real Estate Equities (NYSE: ARE) marked its 32nd anniversary on Jan 5, 2026, highlighting its role as a pioneer in life science real estate and Megacampus ecosystems that support drug development and innovation.
Key reported metrics through Sept 30, 2025: 71% of annual rental revenue came from Greater Boston, San Francisco Bay Area, and San Diego; Megacampus occupancy was 91% (+18% vs. market); combined leasing volume in those three markets equaled ~105% of the next five largest owners from Jan 1, 2023–Sept 30, 2025; and five-year average tenant retention exceeded 80%. The company also said 39% of the 44 novel therapies approved by FDA in 2025 were developed or commercialized by Alexandria tenants.
Alexandria plans a public-private partnership MAP-D clinical study targeting a May 2026 launch to identify biomarkers for depression.
Alexandria Real Estate Equities (NYSE: ARE) will host a conference call and audio webcast on Tuesday, January 27, 2026 at 2:00 p.m. ET to discuss its fourth quarter and year end 2025 operating and financial results.
The company will release results after market close on Monday, January 26, 2026. To join the live call dial (833) 366-1125 (U.S./Canada) or (412) 902-6738 (international) and ask the operator for Alexandria Real Estate Equities. The live webcast is available at http://investor.are.com/webcasts.
A replay is available from 4:00 p.m. ET on January 27, 2026 through 4:00 p.m. ET on February 3, 2026; dial (855) 669-9658 (U.S./Canada) or (412) 317-0088 (international) and enter access code 4730896.
Alexandria Real Estate Equities (NYSE: ARE) announced that its Board authorized a refreshed common stock repurchase program of up to $500 million, replacing the prior authorization that was set to expire December 31, 2025.
Under the prior program the company repurchased $258.2 million of common stock, primarily in January 2025. The new authorization permits purchases in the open market or by negotiated transactions, accelerated share repurchases, indirect purchases including derivatives, or other transactions through December 31, 2026. Repurchases are discretionary, may be suspended, and will depend on price, available capital, market and economic conditions. The company said its preference is to fund repurchases on a leverage-neutral basis using operating cash after dividends and proceeds from property dispositions or joint ventures.
Alexandria Real Estate Equities (NYSE: ARE) announced a quarterly cash dividend of $0.72 per common share for 4Q25, a 45% reduction from the 3Q25 dividend. The dividend is payable on January 15, 2026 to holders of record on December 31, 2025. The board said the reduction aims to fortify the balance sheet, enhance financial flexibility and preserve approximately $410 million of liquidity on an annual basis. Based on the closing share price on December 1, 2025, the dividend implies a common-stock yield of 5.4%.
Alexandria Real Estate Equities (NYSE: ARE) reported 3Q25 results for the quarter ended September 30, 2025: Net loss per share diluted $(1.38) and YTD net loss per share diluted $(2.09), while FFO per share diluted, as adjusted was $2.22 for 3Q25 and $6.85 YTD. Operating occupancy was 90.6% with tenant collections at 99.9%. Leasing volume totaled 1.2M RSF in 3Q25, including a 466,598 RSF, 16-year build-to-suit expansion. Liquidity totaled $4.2B; net debt and preferred to Adjusted EBITDA was 6.1x (3Q25 annualized). The board declared a common dividend of $1.32 for 3Q25 (12-month dividend $5.28; yield 6.3%).
Alexandria Real Estate Equities (NYSE: ARE) and Alexandria Venture Investments received the 2025 Charles A. Sanders, MD, Partnership Award from the Foundation for the National Institutes of Health on October 22, 2025.
The award recognizes Alexandria's leadership in launching a public-private precision medicine partnership, MAP-D (Multi-Level Assessment & Phenotyping in Depression), developed with NIMH, FDA, VA, research institutions, industry partners, and patient advocates. MAP-D completed its critical design phase and targets a Phase 1 launch in May 2026 to assemble a comprehensive depression dataset and validate biomarkers to guide individualized treatment.
Alexandria Real Estate Equities (NYSE:ARE) has announced the opening of Lilly Gateway Labs San Diego at their One Alexandria Square Megacampus in Torrey Pines. This strategic partnership with Eli Lilly and Company represents an expansion of the Gateway Labs platform, which has already fostered the development of over 50 novel therapeutics across its existing locations.
The new facility combines ARE's real estate infrastructure and operations expertise with Lilly's scientific resources, mentorship, and venture capital network. Located in a LEED Gold certified all-electric laboratory facility, the hub features modular labs, collaboration spaces, and advanced scientific equipment. Initial tenants include venture-backed biotech companies focusing on Alzheimer's, Parkinson's, cardiovascular diseases, and oncology research.
Alexandria Real Estate Equities (NYSE:ARE), a leading owner and developer of life science Megacampus™ ecosystems, has been recognized by Newsweek as one of the World's Most Trustworthy Companies for the second consecutive year. The company recently secured its largest life science lease ever for a 466,598 RSF build-to-suit biomedical research hub at Campus Point Megacampus.
Key financial metrics include a strong balance sheet with the longest remaining debt term among S&P 500 REITs, 75% of annual rental revenue from its Megacampus platform, and a 7.4-year weighted-average lease term. The company maintains an impressive 80% tenant retention rate and generates 53% of annual rental revenue from investment-grade and publicly traded large-cap companies.
Alexandria Real Estate Equities (NYSE:ARE) has declared a quarterly cash dividend of $1.32 per common share for the third quarter of 2025, payable on October 15, 2025, to stockholders of record on September 30, 2025.
The company is maintaining its dividend level instead of continuing its historical 4.5% growth rate, which will provide additional liquidity of over $40 million annually. The current dividend represents a 7.3% yield based on the June 30, 2025 closing price, with a favorable dividend payout ratio of 57% for Q2 2025.